Study Evaluating LXR-623 in Healthy Japanese Adults
Launched by WYETH IS NOW A WHOLLY OWNED SUBSIDIARY OF PFIZER · Oct 6, 2006
Trial Information
Current as of July 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy, Japanese Males aged 20-45 years
- Exclusion Criteria:
- • A history or active presence of clinically important medical disease
About Wyeth Is Now A Wholly Owned Subsidiary Of Pfizer
Wyeth, now a wholly owned subsidiary of Pfizer, is a global biopharmaceutical company dedicated to advancing healthcare through innovative research and development. With a strong legacy in the pharmaceutical industry, Wyeth focuses on discovering and delivering medicines that address significant medical needs across various therapeutic areas, including vaccines, biologics, and specialty pharmaceuticals. Leveraging Pfizer's extensive resources and expertise, Wyeth continues to drive scientific advancement and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toshima Ku, Tokyo, Japan
Patients applied
Trial Officials
Medical Monitor
Study Director
Wyeth is now a wholly owned subsidiary of Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials